Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study
| Autor: | Marc Alexander Radtke, Alexander A. Navarini, Ulrich Mrowietz, Kristian Reich, Wolf-Henning Boehncke, Lars E. French, Florian Anzengruber, Peter Häusermann, Diamant Thaçi, Matthias Augustin, C. Sorbe, Curdin Conrad, Lara Valeska Maul, Julia-Tatjana Maul |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Treatment response medicine.medical_specialty Registry study Treatment outcome Dermatology Systemic therapy Severity of Illness Index Dermatologic Agents / therapeutic use 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Psoriasis Internal medicine medicine Humans Psoriasis / drug therapy Prospective Studies Registries Multi centre ddc:616 business.industry medicine.disease humanities Treatment Outcome Male patient Non interventional Quality of Life Female Dermatologic Agents business |
| Zdroj: | British journal of dermatology, Vol. 185, No 6 (2021) pp. 1160-1168 |
| ISSN: | 0007-0963 |
| Popis: | Background Psoriasis is a stigmatizing disease that often affects female patients more negatively than male patients. Very little systematic data on the treatment responses related to gender exists. Objectives This two-country, multi-centre, prospective, non-interventional registry study aimed to evaluate potential gender differences with respect to systemic anti-psoriatic treatment. Methods Data of patients with moderate to severe psoriasis participating in the German (PsoBest) or Swiss (SDNTT) psoriasis registry were analysed. Treatment response was defined as reaching PASI75 or PASI ≤ 3 at months 3, 6 and 12 of treatment and was supplemented by patient reported outcomes, i.e. DLQI ≤ 1 and Delta DLQI ≥ 4. Results 5,346 patients registered between 2007 and 2016 were included in the analyses (4,896 from PsoBest and 450 from SDNTT). The majority of patients received a non-biologic treatment: 67.3 % of male and 69.8 % of female patients. Overall, women showed slightly higher PASI response rates after 3, 6 and 12 months, respectively 54.8 vs. 47.2 %, p ≤ 0.001, 70.8 vs. 63.8 %, p ≤ 0.001, 72.3 vs. 66.1%, p ≤ 0.004. In line with this, we found significantly higher proportions of female patients achieving a DLQI reduction ≥ 4: 61.4 vs 54.8 % at month 3 (p ≤ 0.001), 69.6 vs. 62.4 % at month 6 (p ≤ 0.001) and 70.7 vs. 64.4 % at months 12 (p ≤ 0.002), respectively. Females on biologics showed a significantly superior treatment response in the PASI ≤ 3 at 3 (57.8 vs 48.5%) p ≤ 0.004 and 6 months (69.2 vs 60.9%) p ≤ 0.018. The non-biologics group had a significant better treatment response (PASI response, PASI 75 and PASI ≤ 3) in females over the whole treatment year. Differences found in single treatments only occurred at individual points in time and did not show a uniform trend or can be regarded as methodological artefacts. Conclusion Our data provide evidence that women experience better treatment outcome as measured by PASI to systemic anti-psoriatic therapy than men. Several factors may contribute to this observation, including adherence to treatment, weight, or different lifestyle behavior. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text